BioCryst (BCRX) Beats On Earnings & Sales

BioCryst Pharmaceuticals, Inc. (BCRX) reported fourth quarter EPS of ($0.16) before the bell Wednesday, compared to the consensus estimate of ($0.20). Revenues declined 49.1 percent from $10.6 million yoy to $5.4 million. Analysts expected revenues of $3.7 million. The stock is now up 1.68% to $10.30 on nearly 51K shares. For the year, the drugmaker reported […] View the full post at: BioCryst (BCRX) Beats On Earnings & Sales Related posts: Existing Home Sales Increased 6.8% in March, NAR Goldman Sachs First Quarter Magic Trick Warrant Sales Could Cost Government $10 Billion